Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study

Abstract A second autologous stem‐cell transplantation (ASCT2) is considered for relapsed multiple myeloma (RMM) patients showing prolonged response after a first ASCT. However, given breakthrough treatments like anti‐CD38 and immunotherapy, its role remains debated. We conducted a real‐life study i...

Full description

Bibliographic Details
Main Authors: Axel André, Lydia Montes, Damien Roos‐Weil, Laurent Frenzel, Marguerite Vignon, Thomas Chalopin, Pierre‐Edouard Debureaux, Alexis Talbot, Agathe Farge, Fabrice Jardin, Karim Belhadj, Bruno Royer, Jean‐Pierre Marolleau, Bertrand Arnulf, Pierre Morel, Stéphanie Harel
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.106

Internet

https://doi.org/10.1002/hem3.106

Similar Items